The Paris office of international law firm Simmons & Simmons LLP announces that it has advised Eisai S.A.S, the French subsidiary of Eisai Co., Ltd., on the transfer of its rights in France and Algeria in respect of Loxapac® (loxapine) and Parkinane LP® (trihexyphenidyl chloride) to CNX Therapeutics Limited, a speciality pharmaceutical company, for €56.5 million in cash. Loxapac® and Parkinane LP® are CNS products used to treat psychological disorders and Parkinson’s disease respectively.
The multidisciplinary Simmons team was led by Paris based corporate M&A partner Christian Taylor, and comprised:
Anna Velitchkova (Of Counsel), Alexandre Vernisse and Domitille Cabaud (associates) on the corporate M&A aspects
Anne-Catherine Perroy (Of Counsel), Pierre-Alexis Maingon and Albane Drissi (associates) on the regulatory aspects
Frédérique Potin (Of Counsel), Hélène Choquet and Guillaume Tran (associates) on the French IP aspects
Claire le Touzé (Of Counsel) and Solène Blandin (associate) on the employment law aspects
